Pimavanserin

CHEMBL2111101 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

427.6 g/mol

LogP

4.5

Phase

4

Used to treat hallucinations and delusions that occur in people with Parkinson's disease psychosis by selectively blocking certain serotonin receptors in the brain without affecting dopamine pathways. This targeted approach makes it particularly suitable for Parkinson's patients who cannot tolerate medications that block dopamine.

Molekularmasse

427,6000 g/mol

LogP

4,50

TPSA

44,80 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Alzheimer's Disease Parkinson's Disease Schizophrenia Insomnia Major Depressive Disorder

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1

InChI

InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)

Molecular Formula

C25H34FN3O2

HBD / HBA

1 / 4

Rotierbare Bindungen

8

Schwere Atome

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Used to treat hallucinations and delusions that occur in people with Parkinson's disease psychosis by selectively blocking certain serotonin receptors in the brain without affecting dopamine pathways. This targeted approach makes it particularly suitable for Parkinson's patients who cannot tolerate medications that block dopamine.

Yes, Pimavanserin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111101. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 10071196. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Pimavanserin auf PillFYI

Struktur

Schnelldaten

Formel: C25H34FN3O2
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.